Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $90.63 Average PT from Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received an average recommendation of “Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $90.63.

A number of research firms recently issued reports on KROS. Oppenheimer initiated coverage on Keros Therapeutics in a research note on Tuesday, June 25th. They set an “outperform” rating and a $102.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, June 18th. Guggenheim began coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective on the stock. Bank of America lowered their target price on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Finally, Truist Financial reissued a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Tuesday, June 18th.

Keros Therapeutics Stock Down 0.7 %

Shares of KROS stock opened at $59.67 on Friday. Keros Therapeutics has a 12-month low of $27.02 and a 12-month high of $73.00. The firm has a fifty day moving average of $51.27 and a 200-day moving average of $52.28. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -11.59 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The business had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same period last year, the firm posted ($1.27) earnings per share. Research analysts expect that Keros Therapeutics will post -4.88 earnings per share for the current year.

Insider Transactions at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of Keros Therapeutics stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of KROS. Handelsbanken Fonder AB boosted its holdings in shares of Keros Therapeutics by 21.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 9,700 shares of the company’s stock valued at $563,000 after buying an additional 1,700 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Keros Therapeutics in the second quarter valued at $128,000. Nantahala Capital Management LLC lifted its stake in Keros Therapeutics by 28.8% in the second quarter. Nantahala Capital Management LLC now owns 378,807 shares of the company’s stock valued at $17,311,000 after acquiring an additional 84,810 shares during the last quarter. Algert Global LLC grew its position in shares of Keros Therapeutics by 10.6% in the 2nd quarter. Algert Global LLC now owns 15,700 shares of the company’s stock valued at $717,000 after acquiring an additional 1,505 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Keros Therapeutics by 17.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,833 shares of the company’s stock worth $769,000 after purchasing an additional 2,517 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.